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One hundred seven asymptomatic patients who underwent 
intravenous dipyridamole thallium imaging were evaluated 
to determine prognostic indicators of subsequent cardiac 
events over an average follow-up period of 14 + 10 months. 
Univariate analysis of 18 clinical, scintigraphic and angio- 
graphic variables revealed that a reversible thallium defect, 
a combined fixed and reversible thallium defect, number of 
segmental thallium defects and extent of coronary artery 
disease were significant predictors of subsequent cardiac 
events. Of the 13 patients who died or had a nonfatal 
infarction, 12 had a reversible thallium defect. 
Stepwise logistic regression analysis selected a reversible 
thallium defect as the only significant predictor of cardiac 
The importance of silent myocardial ischemia as an adverse 
prognostic risk factor in patients with coronary artery dis- 
ease has been well described (1-4). The most common 
noninvasive test procedures used to detect silent myocardial 
ischemia are the 24 h ambulatory electrocardiogram (ECG) 
and exercise testing, either alone or with radionuclides (4-9). 
A sizable fraction of patients with coronary artery disease 
are unable to perform an adequate level of exercise to test 
cardiac reserve. Intravenous dipyridamole thallium scintig- 
raphy is a useful alternative in this type of patient and has 
been reported (IO-131 to have adequate diagnostic and 
prognostic efficacy in patients with coronary artery disease. 
However, the test has not been evaluated in asymptomatic 
patients. 
The purpose of this report is to examine the prognostic 
value of intravenous dipyridamole thallium scintigraphy in 
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events. When death or myocardial infarction was the 
outcome variable, a combined fixed and reversible thallium 
defect was the only predictor of outcome. In patients 
without previous myocardial infarction, the cardiac event 
rate was significantly greater in those with an abnormal 
versus normal thallium scan (55% versus 12%) p < 0.001). 
Thus, intravenous dipyridamole thallium scintigraphy is 
a useful noninvasive test to risk stratify asymptomatic 
patients with coronary artery disease. A reversible thallium 
defect most likely indicates silent myocardial ischemia in a 
sizable fraction of patients in this clinical subset and is 
associated with an unfavorable prognosis. 
(,I Am Co11 Cardiol1989;14:1635-41) 
asymptomatic patients and to determine whether a revers- 
ible thallium defect is associated with an adverse clinical 
outcome and suggests that the defect might indicate silent 
myocardial ischemia. 
Methods 
Study patients (Table 1). Between July 1984 and March 
1988, 1.420 patients had intravenous dipyridamole thallium 
scintigraphy at St. Louis University Hospital, including 107 
asymptomatic patients with coronary artery disease. The 
mean age of the latter 66 men and 41 women was 63 years 
(range 34 to 87). All patients were free of angina pectoris for 
at least 6 months before the dipyridamole test. Of the 107 
patients, 33 had a previous myocardial infarction, 15 had 
previous coronary bypass surgery and 32 patients had pre- 
vious angioplasty. The indications for the dipyridamole test 
were symptomatic peripheral vascular disease in 28 patients, 
stroke in 2 and preoperative clearance for major noncardiac 
surgery in 26. The remaining 51 patients had poor exercise 
tolerance. Clinical and angiographic findings in the 107 
patients are also summarized in Table 1. 
Written informed consent was obtained from all patients 
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Table 1. Clinical and Angiographic Characteristics of 107 
Asymptomatic Patients With Documented Coronary 
Artery Disease 
Age (yr) 63* 11 
Men 66 (62%) 
Hypertension 47 (44%) 
Diabetes mellitus 26 (24%) 
Previous MI 33 (30%) 
Previous PTCA 32 (30%) 
Previous CABG 15 (14%) 
Medication 
Beta blocker 26 (24%) 
Calcium channel blocker 56 (52%) 
Nitroglycerin 56 (52%) 
Cardiac catheterization (n = 96) 
Coronary artery disease 
Nonsignificant 11 (12%) 
One VD 30 (31%) 
Two VD 23 (24%) 
Three VD 32 (33%) 
LVEF (n = 86) 0.61 k 0.13 
CABG = coronary artery bypass surgery; LVEF = left ventricular 
ejection fraction; MI = myocardial infarction; PTCA = percutaneous trans- 
luminal coronary angioplasty; VD = vessel disease ~50% stenosis. 
before intravenous dipyridamole infusion. All patients con- 
sented to a clinical investigation protocol approved by the 
Institutional Review Board at St. Louis University School of 
Medicine. 
Dipyridamole infusion protocol. Dipyridamole infusion 
was performed in the morning, with the patient fasting and in 
the supine position. Cardiac medications were stopped 12 h 
before dipyridamole infusion. Aminophylline or its deriva- 
tives were stopped 48 h before the study. Dipyridamole was 
infused at a rate of 0.56 mg/kg body weight over 4 min 
through an indwelling intravenous catheter after baseline 
heart rate and blood pressure were recorded in the supine 
position. The ECG was continuously monitored. Heart rate, 
blood pressure and the ECG were recorded each minute for 
a total of 10 min from the start of the infusion. The patient 
was instructed to sit up and start active leg swinging for 4 
min after the termination of the infusion, following which 2 
mCi of thallium-201 was injected through the catheter. The 
patients were closely monitored for any side effects after the 
infusion and during the imaging phase. Aminophylline and 
nitroglycerin were available to reverse any side effects. No 
significant complications were noted as a result of the 
dipyridamole infusion. 
Thallium-201 imaging and analysis. Planar thallium imag- 
ing was performed within 5 min after the injection of the 
isotope, using a small field of view gamma camera (Elscint) 
equipped with a low energy, high resolution, parallel hole 
collimator. Sequential images were performed in the 45” left 
anterior oblique, anterior and left lateral views, which were 
acquired at the 80 keV photo peak with 30” window and 
stored on 256 x 256 byte matrix. Approximately 500,000 
counts were acquired during 10 min for each image. Redis- 
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tribution images were obtained in the same views 4 h later. 
The images were analyzed by two observers without prior 
knowledge of the patient’s clinical history or angiographic 
results. 
The thallium images of the left ventricle were divided into 
5 approximate regions and 15 regional segments. Each 
segment was coded as normal or as having a reversible or 
fixed thallium defect. An abnormal thallium scan was defined 
as the presence of a reversible, fixed or combined defect 
(reversible and fixed defect in different segments). Silent 
myocardial ischemia was defined as the presence of a 
reversible or combined thallium defect without chest pain 
during or after the dipyridamole infusion. Of the 107 pa- 
tients, 96 underwent coronary angiography and had no new 
cardiac events between the time of testing and time of 
angiography. The average time between the test and coro- 
nary angiography was 1 month. An important coronary 
narrowing was defined as the presence of a 50% luminal 
diameter stenosis in any of the major coronary arteries. Each 
coronary angiogram was interpreted by a cardiologist who 
was unaware of the noninvasive test results. 
Follow-up. The patients were followed up for an average 
of 14 months (range 1 to 40) by telephone interview or clinic 
visit. The minimal follow-up period was 6 months in the 
absence of a cardiac event. A cardiac event was defined as 
either cardiac death, nonfatal myocardial infarction, unsta- 
ble angina pectoris, occurrence of functional class III or IV 
angina or the need for a revascularization procedure. 
Statistical analysis. Univariate and stepwise logistic re- 
gression analyses were performed with use of clinical, angio- 
graphic and radionuclide variables. There were two outcome 
variables: a cardiac event or the combined end point of death 
or nonfatal myocardial infarction. Frequencies were com- 
pared by chi-square analysis. A p value co.05 was consid- 
ered statistically significant. 
The variables analyzed were age, gender, history of 
hypertension, diabetes mellitus, smoking, previous myocar- 
dial infarction, previous coronary artery bypass surgery, 
previous coronary angioplasty, use of a beta-adrenergic 
blocking agent, use of a calcium channel blocking agent, ST 
depression during dipyridamole infusion, thallium scintigra- 
phy (normal versus abnormal), reversible thallium defect, 
fixed thallium defect, combined (reversible and fixed) thal- 
lium defect, number of segmental thallium defects, presence 
or absence of significant coronary artery disease, number of 
stenotic coronary arteries with ~50% stenosis and global left 
ventricular ejection fraction. Actuarial event rates were 
analyzed with Kaplan-Meier survival curves. Differences in 
the event rates were calculated by using the Mantel-Cox test 
over the total duration of follow-up. 
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Table 2. Number and Percent Cardiac Events in 107 Patients 
With Normal, Reversible, Fixed and Combined Myocardial 
Thallium Defects 
ho. 
(VI 
24 Month Cumulative Event-Free 
Anv Event (7~) Death or Ml (‘So) 
Normal 36 (34) 93 + 5 100 s 
Fixed 24 (22) 67213 * 9327 t 
Reversible 27 (2.0 II If- 10 65 + I5 
Combined 20 119) 44 + II 58 + I? , 
*p < 0.0001, tp = 0.0007 (Mantel-Cox test). MI = myocardial infarction. 
Event data are reported as mean values +_ standard error of the estimate. 
Results 
The dipyridamole thallium scan was normal in 36 (34%) of 
the 107 patients. Of the remaining 71 patients who had an 
abnormal thallium scan, 25%, 22% and 19% of the patients 
had a reversible, fixed or combined thallium defect, respec- 
tively. The patients who died or had a myocardial infarction 
had a larger perfusion defect on thallium imaging (5.4 1- 2 
versus 2.4 ? 2.6. p < 0.01). The total cardiac event rate in 
the study group was 36%. The incidence of cardiac death or 
nonfatal myocardial infarction was 12%; there were five 
deaths and eight myocardial infarctions (seven were nonfa- 
tal). 
There were no statistically significant differences in the 
mean age, history of previous coronary angioplasty, previ- 
ous coronary bypass surgery or extent of coronary artery 
disease between patients with or without previous myocar- 
dial infarction. Left ventricular ejection fraction was signif- 
icantly decreased in patients with versus without prior 
myocardial infarction (0.53 ? 0.12 versus 0.63 2 0. I I, p < 
0.01). 
Prognosis of patients with normal versus abnormal thal- 
lium scan (Table 2). The 36 patients who had a normal 
intravenous dipyridamole thallium scan were compared with 
the 71 patients who had an abnormal scan. The number of 
deaths or nonfatal myocardial infarcts was significantly 
greater when the scan was abnormal (13 versus 0; p < 0.01). 
The patients with an abnormal scan had a significantly higher 
rate of class III or IV angina pectoris and need for coronary 
revascularization compared with patients with a normal scan 
(p < 0.0001). When patients with an abnormal thallium scan 
were stratified according to the presence of a reversible, 
fixed or combined thallium defect, the cardiac event rate was 
significantly greater in patients who had a reversible or 
combined defect than in those who had a normal thallium 
scan or a fixed thallium defect (Table 2) (Fig. I). When the 
analyses were limited to the combined end point of death or 
myocardial infarction, the event rate was highest in the 
patients who had a combined or reversible thallium defect 
(Fig. 2). Of the I3 patients who died or had a nonfatal 
myocardial infarction, I2 had a reversible or partially revers- 
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Figure 1. Incidence of cardiac events in 107 asymptomatic patients 
with coronary artery disease stratified by intravenous dipyridamole 
(DIP) thallium (TL) results. See text for definition of cardiac events. 
N = number of patients at entry. 
ible thallium defect and 10 had multivessel coronary artery 
disease (Fig. 3). 
Baseline clinical characteristics of the patients who had a 
cardiac event were similar to those of patients who did not 
have a cardiac event during the follow-up period. However, 
patients who had a cardiac event during this period had a 
significantly greater rate of reversible thallium defect (83% 
versus 47%. p < 0.01) and a greater frequency of multivessel 
coronary artery disease (72% versus 53%, p < 0.05). 
Univariate analysis (Table 3). Univariate analysis of clin- 
ical, angiographic and scintigraphic variables was performed 
to identify risk factors for cardiac events. An abnormal 
thallium scan, a reversible thallium defect, a combined 
thallium defect, the number of perfusion defects and the 
angiographic extent of coronary artery disease were signifi- 
cant predictors of subsequent cardiac events. When the 
outcome variable was limited to death or myocardial infarc- 
tion, univariate predictors were age, an abnormal thallium 
scan, a reversible thallium defect, a combined thallium 
Figure 2. Incidence of death or myocardial infarction (MI) in 107 
asymptomatic patients with coronary artery disease stratified by 
intravenous dipyridamole (DIP) thallium (TL) results. A reversible 
or combined thallium defect significantly increased the risk of this 
end point (p < 0.0001). 
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defect, number of segments 
use of beta-blockers. 
with perfusion defects and the 
Logistic regression analysis (Table 4). Stepwise logistic 
regression analyses of the entire variable set in 86 patients or 
when the angiographic variables were removed (107 pa- 
tients) revealed the presence of a reversible thallium defect 
as the only significant predictor of a cardiac event. When the 
outcome variable was limited to death or myocardial infarc- 
tion, the presence of a combined thallium defect was the 
only significant variable predictive of outcome. 
Myocardial infarction. The study group was stratified by 
history of previous myocardial infarction. Among the 74 
patients without previous myocardial infarction, the total 
cardiac event rate was 12% when the thallium scan was 
normal versus 55% when it was abnormal (p < 0.001). There 
Table 3. Univariate Analysis to Predict Cardiac Events, Death or 
Myocardial Infarction in 107 Asymptomatic Patients With 
Coronarv Artery Disease 
Any Event Death or Ml 
J p Value J p Value 
Reversible TL defect 25.444 <O.OOl 11.378 <O.OOl 
Abnormal TL 15.618 <O.OOl 6.901 0.009 
Combined TL defect 7.812 0.006 21.059 <O.OOl 
No. of segmental TL defects 7.270 0.008 14.123 <O.OQl 
Extent of CAD 4.041 0.047 3.069 0.083 
ST depression 3.524 0.063 1.026 0.313 
Calcium channel blocker 3.310 0.071 0.130 0.908 
Age 1.963 0.164 5.566 0.020 
Beta-blocker 1.983 0.162 3.911 0.050 
PTCA 0.001 0.974 3.612 0.061 
CAD = coronary artery disease; TL = thallium: other abbreviations as in 
Table I. 
Figure 3. Thallium scans of a 65 year old 
patient with a history of myocardial infarction 
and coronary bypass surgery who died sud- 
denly 6 months after the dipyridamole test. 
The upper panels reveals the postinfusion 
images and the lower panels show the 4 h 
redistribution images. A small reversible api- 
cal defect is noted by the solid arrow and a 
large fixed defect in the posterobasal, postero- 
lateral and inferior segment of the heart is 
indicated by an open arrow. ANT = anterior; 
45 LAO = 45” left anterior oblique; LT 
LAT = left lateral. 
were no deaths or myocardial infarctions in the 30 patients 
with a normal thallium scan, whereas 9 patients with an 
abnormal scan died or had a myocardial infarction. 
Among the 33 patients with previous myocardial infarc- 
tion, there were no cardiac events when the scan was normal 
compared with an event rate of 33% when the scan was 
abnormal (p < 0.01). The incidence of death or recurrent 
myocardial infarction was 0 when the scan was normal 
compared with 15% when the scan was abnormal. 
Discussion 
Significance of dipyridamole-induced thallium defect. The 
clinical evaluation of asymptomatic patients with coronary 
artery disease includes atherosclerotic risk factor evaluation 
and noninvasive testing to detect the presence and severity 
of myocardial ischemia. Dynamic stress testing with or 
without radionuclides is a common test procedure to detect 
myocardial ischemia and can be used to identify high risk 
patients in whom coronary angiography would be indicated. 
Intravenous dipyridamole thallium imaging is a useful alter- 
native to exercise testing in patients who cannot exercise. 
The ECG features of intravenous dipyridamole thallium 
imaging are limited and, in the present series, only 7% of 
patients had dipyridamole-induced ST segment depression 
rl mm over baseline, similar to that observed in previous 
reports (14,15). The functional significance of a dipyrida- 
mole-induced thallium defect was evaluated by Labovitz et 
al. (16); they observed that a reversible thallium defect 
correlated strongly with the development of new wall motion 
abnormalities detected by echocardiography. Picano et al. 
(17) reported dipyridamole-induced wall motion abnormali- 
ties detected by echocardiography in a sizable fraction of 
JACC Vol. 14, No. 7 
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‘Table 4. Stepwise Logistic Regression to Predict Cardiac Events. Death or Myocardial Infarction 
in 107 Asymptomatic Patients With Coronary Artery Disease 
Any Even1 
2 p Value 
With Angiographic Variable, 
Death or MI 
P p Value 
Reversible TL defect 
Combined TL defect 
Calcium channel blocker 
ST depression 
No. of segmental TL defects 
Extent of CAD 
Beta-blocker 
19.431 <O.OOl 
0.114 0.967 
2.373 0. 106 
1.776 0.196 
I.324 0.186 
0.59 I 0.51’) 
Without Angiogrdphic Variable> 
0.436 0.4x7 
5.616 0.010 
- 
- 
0.659 0.569 
- 
I.361 0.112 
Reversible TL defect 
Combined TL defect 
Calcium channel blocker 
ST segment depression 
No. of segmental TL defects 
Beta-blocker 
Abbreviations as in Table 3 
25.893 <O.OOl 0.2X 0.1x5 
0.919 0.233 9.969 %O.OOl 
3.162 0.08 I - 
I .761 0.‘41 - 
0.70 0.677 0.941 0.3x3 
3.800 O.Ohl 
patients with obstructive coronary artery disease. Thus, the 
presence of dipyridamole-induced thallium defects is often 
associated with functional determinants of myocardial ische- 
mia, such as development of new regional wall motion 
abnormalities as a result of a coronary steal phenomenon. 
However, some patients may have dipyridamole-induced 
abnormal flow reserve in the absence of obvious evidence of 
myocardial ischemia. 
Prognostic value of exercise and dipyridamole thallium 
imaging. Our data show that intravenous dipyridamole- 
induced thallium defects are powerful predictors for future 
cardiac events in asymptomatic patients with documented 
coronary artery disease. A reversible thallium defect was the 
only significant predictor of future cardiac events during the 
follow-up period, whereas the presence of a combined fixed 
and reversible thallium defect was predictive of death or 
myocardial infarction, even after consideration of angio- 
graphic variables such as extent of coronary artery disease 
and global left ventricular ejection fraction. When the angio- 
graphic data were removed from analysis, only the radionu- 
elide variables were predictive of cardiac events (Table 4). 
In symptomatic patients with coronary artery disease, 
exercise thallium scintigraphy provides useful prognostic 
information even after adjustment for cardiac catheterization 
variables (18,191, and the presence and extent of reversible 
thallium defects were powerful predictors of cardiac events 
(19). Brown et al. (20) reported that the number of myocar- 
dial segments demonstrating a reversible thallium defect was 
the only significant predictor of future cardiac events in 
patients with coronary artery disease without previous myo- 
cardial infarction among multiple clinical, angiographic and 
exercise variables examined. Iskandrian et al. (21) reported 
that the extent of exercise-induced thallium perfusion de- 
fects identifies patients at increased risk of death and myo- 
cardial infarction. In the present series of asymptomatic 
patients. the number of myocardial segments exhibiting a 
thallium perfusion defect was a significant univariate predic- 
tor of death or myocardial infarction. Several authors (22- 
24) have reported that symptomatic patients with a normal 
exercise thallium scan have a low incidence of death or 
myocardial infarction over several years of follow-up evalu- 
ation. 
Our data, obtained with intravenous dipyridamole thal- 
lium scintigraphy, confirm these observations in asympto- 
matic patients with stable coronary artery disease who were 
unable to exercise and identify a clinical patient subset in 
which coronary angiography would not be required to deter- 
mine prognosis over the short-term. The overall prognosis in 
our patients indicates a relatively low risk group with an 
average ejection fraction of 0.61. A greater number of events 
would be expected in a group of patients with more impaired 
left ventricular function. Exercise radionuclide angiography 
is another useful noninvasive test predictive of cardiac 
events in patients with chronic ischemic heart disease (25). 
Silent myocardial &hernia detected by thallium scintigra- 
phy. There are few prognostic data reported on the use of 
dipyridamole thallium imaging in asymptomatic patients 
with coronary artery disease. Identification of a reversible 
thallium defect in the asymptomatic subject might indicate 
silent myocardial ischemia if the defect is associated with an 
increased risk of cardiac events. particularly because a 
dipyridamole-induced thallium defect is correlated with 
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echocardiographic determinants of impaired left ventricular 
function (16). Assey et al. (5) followed up 55 patients with 
angiographically documented coronary artery disease for 30 
months after an exercise thallium scan. The patients were 
stratified into two groups according to the presence or 
absence of angina during exercise. Each patient had a 
reversible myocardial defect during the exercise thallium 
scintigram. During follow-up study, the incidence of cardiac 
death or myocardial infarction was significantly greater in 
the group without angina. Leppo et al. (11) reported a high 
incidence of death and reinfarction in 51 survivors of acute 
myocardial infarction when the predischarge dipyridamole 
thallium scan showed a reversible defect. In their series, a 
reversible thallium defect was the only predictor for future 
cardiac events in this clinical patient subset. In our experi- 
ence, a reversible thallium defect is a significant predictor of 
cardiac events in patients without previous myocardial in- 
farction, even after adjustment for coronary angiographic 
findings (26). 
Silent myocardial ischemia and myocardial infarction. In 
the present series, patients with a previous myocardial 
infarction and a normal intravenous dipyridamole thallium 
scan had no cardiac events, whereas the event rate was 32% 
in those with an abnormal thallium scan. Silent myocardial 
ischemia is a common finding in patients surviving myocar- 
dial infarction. Gibson et al. (27) reported that the presence 
of delayed redistribution or a thallium defect in more than 
one vascular territory increased the risk of cardiac events in 
survivors of uncomplicated myocardial infarction. Absence 
of redistribution identified a low risk patient group. 
The pathophysiology of silent myocardial ischemia is not 
well defined, although a defective pain perception and an 
abnormally high pain threshold are postulated as possible 
mechanisms (28,29). The myocardial ischemic threshold can 
be surpassed either by an increase in myocardial oxygen 
demand or by a reduction in coronary flow. Dipyridamole is 
a potent systemic and coronary vasodilator, which may 
result in heterogeneous blood flow in the presence of organic 
or dynamic coronary stenoses and which may induce a 
coronary steal that would be detected as a perfusion abnor- 
mality, even though myocardial oxygen demand remains 
unchanged (30). 
Conclusion and clinical implications. This study provides 
new information on asymptomatic subjects with coronary 
artery disease and indicates that a reversible thallium defect 
in these patients is associated with an unfavorable prognosis, 
even in those who have preserved left ventricular function 
and who might be considered at low risk of developing future 
cardiac events. The reversible thallium defect indicates 
regional heterogeneity of coronary blood flow and, in a 
significant fraction of patients, is associated with functional 
evidence of myocardial ischemia and an increased incidence 
of cardiac events. Intravenous dipyridamole thallium imag- 
ing is a useful test to risk stratify asymptomatic patients with 
coronary artery disease who cannot exercise. Patients who 
have a normal scan are at low risk of developing future 
cardiac events, and cardiac catheterization would not be 
indicated in this group. A reversible thallium defect identifies 
patients at increased risk of cardiac events, and the infor- 
mation can be used to help determine whether coronary 
angiography is necessary. 
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